• Trulieve Cannabis recently became the first U.S. cannabis company to list on the New York Stock Exchange after restructuring to separate its federally compliant medical operations from its adult-use business.
• This step, combined with a newly authorized share repurchase program of up to US$50,000,000 or 8,495,038 shares, could broaden institutional access and reshape how investors view Trulieve’s capital allocation priorities.
• Now we’ll explore how Trulieve’s NYSE listing and new buyback authorization may influence the company’s existing investment narrative and risk profile.

Capitalize on the AI infrastructure supercycle with our selection of the 49 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Trulieve Cannabis Investment Narrative Recap

To own Trulieve today, you need to believe in the long term value of a federally compliant medical cannabis platform that can convert regulatory shifts into better cash generation. The NYSE listing and new buyback authorization do not fundamentally change the near term reliance on U.S. rescheduling and 280E relief as the key catalyst, nor do they remove execution risk around new market expansion and store investments in a still-pressured consumer environment.

The newly announced share repurchase program of up to US$50,000,000, or 5% of outstanding subordinate voting shares, stands out as the most relevant development here. It sits alongside Trulieve’s NYSE uplisting as part of a broader capital structure reset that could matter if federal tax relief and DEA registration free up incremental cash, but it also adds another layer for investors to watch around timing, balance sheet flexibility and future investment capacity.

Yet behind the headlines, investors should also be aware that Trulieve’s growth plans in new medical markets such as Texas and Georgia still depend on...

Trulieve Cannabis' narrative projects $906.7 million revenue and $339.0 million earnings by 2029. This assumes an 8.2% yearly revenue decline and a $415.0 million earnings increase from -$76.0 million today.

Uncover how Trulieve Cannabis' forecasts yield a $21.00 fair value, a 122% upside to its current price.

Exploring Other Perspectives

Three members of the Simply Wall St Community currently see Trulieve’s fair value clustered between US$19.42 and US$21.00, highlighting tightly grouped but independent views. Against that backdrop, the company’s dependence on regulatory shifts around federal rescheduling and 280E relief could have a meaningful impact on how those valuations hold up over time, so it is worth comparing several of these perspectives before forming your own view.

Explore 3 other fair value estimates on Trulieve Cannabis - why the stock might be worth over 2x more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Trulieve Cannabis research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Trulieve Cannabis research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Trulieve Cannabis' overall financial health at a glance.

Want Some Alternatives?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• The latest GPUs need a type of rare earth metal called Terbium and there are only 31 companies in the world exploring or producing it. Find the list for free.
• This technology could replace computers: discover 29 stocks that are working to make quantum computing a reality.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.